文献速递心力衰竭与心肌病冠心病

NYHA分级与客观指标及轻度心衰长期预后的关联:PARADIGM-HF二次分析

Associations Between New York Heart Association Classification, Objective Measures, and Long-term Prognosis in Mild Heart Failure: A Secondary Analysis of the PARADIGM-HF Trial.
PubMed 文献 · JAMA Cardiol · 2023-01-01

该研究基于PARADIGM-HF试验,分析8326例随机化时NYHA I-III级患者,发现NYHA I级与II级在NT-proBNP水平和长期预后上高度重叠,NYHA III级事件率更高。NT-proBNP对NYHA分级鉴别力差,高NT-proBNP的NYHA I级患者事件风险显著高于低NT-proBNP者。

要点

  • NYHA I级患者中58%在随机化后第一年功能分级发生变化。
  • NT-proBNP鉴别NYHA I与II级的AUC仅0.51,重叠达93%。
  • NYHA III级事件率显著高于I级(HR 1.84)和II级(HR 1.49)。

核心结论

  • NYHA I级和II级患者在客观指标和长期预后上高度重叠,医生定义的“无症状”功能分级掩盖了部分高风险患者。
  • NYHA分级可能难以区分轻度心衰。

研究设计与样本

  • PARADIGM-HF试验的二次分析,纳入8326例随机化时已知NYHA分级的患者,均经历6-10周沙库巴曲缬沙坦导入期。
  • 比较随机化时NYHA I、II、III级患者,主要终点为心血管死亡或首次心衰住院。

主要发现

  • 389例NYHA I级患者中,228例(58%)在随机化后第一年功能分级改变。
  • NT-proBNP鉴别NYHA I vs II的AUC为0.51(95%CI 0.48-0.54),核密度重叠NYHA I vs II为93%,I vs III为79%,II vs III为83%。
  • NYHA III vs I的HR为1.84(95%CI 1.44-2.37),NYHA III vs II的HR为1.49(95%CI 1.35-1.64),NYHA II vs I的HR为1.24(95%CI 0.97-1.58)。
  • 以NT-proBNP 1600 pg/mL分层,NYHA I级且高NT-proBNP者(n=175)事件率数值上高于任何NYHA分级的低NT-proBNP者:vs I级HR 3.43(95%CI 2.03-5.87),vs II级HR 2.12(95%CI 1.58-2.86),vs III级HR 1.37(95%CI 1.00-1.88)。

临床怎么用

  • 对NYHA I级患者应结合NT-proBNP等客观指标评估风险,避免仅凭“无症状”判断为低危。
  • 高NT-proBNP的NYHA I级患者可能需考虑更积极的疾病修饰治疗。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Heart failure (HF) treatment recommendations are centered on New York Heart Association (NYHA) classification, such that most apparently asymptomatic patients are not eligible for disease-modifying therapies. OBJECTIVES: To assess within-patient variation in NYHA classification over time, the association between NYHA class and an objective measure of HF severity (N-terminal pro-B-type natriuretic peptide [NT-proBNP] level), and their association with long-term prognosis in the PARADIGM-HF trial. DESIGN, SETTING, AND PARTICIPANTS: All patients in PARADIGM-HF were in NYHA class II or higher at baseline and were treated with sacubitril-valsartan during a 6- to 10-week run-in period before randomization. Patients classified as NYHA class I, II, and III in PARADIGM-HF were compared at randomization. EXPOSURES: NYHA class at randomization after 6 to 10 weeks of the run-in period. MAIN OUTCOMES AND MEASURES: Primary outcome was cardiovascular death or first HF hospitalization. Logistic regression models, areas under the receiver operating characteristic curve (AUC), kernel density estimation overlaps, and Cox proportional hazards models were used. RESULTS: The analysis included 8326 patients with known NYHA classification at randomization. Of 389 patients in NYHA class I, 228 (58%) changed functional class during the first year after randomization. Level of NT-proBNP was a poor discriminator of NYHA classification: for NYHA class I vs II, the AUC was 0.51 (95% CI, 0.48-0.54). For NT-proBNP level, estimated kernel density overlap was 93% between NYHA class I vs II, 79% between NYHA I vs III, and 83% between NYHA II vs III. Patients classified as NYHA III displayed a distinctively higher rate of cardiovascular events (NYHA III vs I, hazard ratio [HR], 1.84; 95% CI, 1.44-2.37; NYHA III vs II, HR, 1.49; 95% CI, 1.35-1.64). Patients in NYHA class I and II revealed lower event rates (NYHA II vs I, HR, 1.24; 95% CI, 0.97-1.58). Stratification by NT-proBNP level (<1600 pg/mL or ≥1600 pg/mL) identified subgroups with distinctive risk, such that NYHA class I patients with high NT-proBNP levels (n = 175) had a numerically higher event rate than patients with low NT-proBNP levels from any NYHA class (vs I, HR, 3.43; 95% CI, 2.03-5.87; vs II, HR, 2.12; 95% CI, 1.58-2.86; vs III, HR, 1.37; 95% CI, 1.00-1.88). CONCLUSIONS AND RELEVANCE: In this study, patients in NYHA class I and II overlapped substantially in objective measures and long-term prognosis. Physician-defined "asymptomatic" functional class concealed patients who were at substantial risk for adverse outcomes. NYHA classification might be limited to differentiate mild forms of HF. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT01035255.

来源:JAMA Cardiol,查看原文。版权归原作者所有。

引用

  1. Rohde, Zimerman, Vaduganathan, et al. Associations Between New York Heart Association Classification, Objective Measures, and Long-term Prognosis in Mild Heart Failure: A Secondary Analysis of the PARADIGM-HF Trial. JAMA Cardiol. 2023. PMID: 36477809. doi:10.1001/jamacardio.2022.4427

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。